Drugs Containing Excipient (Inactive Ingredient) ETHYL VANILLIN

Branded drugs containing ETHYL VANILLIN excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
E-Z-EM Canada Inc	VARIBAR PUDDING	barium sulfate	32909-125	ETHYL VANILLIN
ESTEVE PHARMACEUTICALS SA	METOPIRONE	metyrapone	68118-455	ETHYL VANILLIN
HRA Pharma Rare Diseases	METOPIRONE	metyrapone	76336-455	ETHYL VANILLIN

Generic drugs containing ETHYL VANILLIN excipient

Company	Ingredient	NDC	Excipient
Rebel Distributors Corp	azithromycin monohydrate	21695-548	ETHYL VANILLIN
E-Z-EM Canada Inc	barium sulfate	32909-125	ETHYL VANILLIN
MedVantx Inc	azithromycin monohydrate	66116-524	ETHYL VANILLIN
ESTEVE PHARMACEUTICALS SA	metyrapone	68118-455	ETHYL VANILLIN
HRA Pharma Rare Diseases	metyrapone	76336-455	ETHYL VANILLIN

Ethyl Vanillin Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: August 2, 2026

Ethyl vanillin is a synthetic aromatic compound used primarily as a flavoring and taste-masking agent in oral pharmaceutical products. Its pharmaceutical market is smaller than its food, beverage, confectionery, and fragrance markets. Demand is likely to grow steadily rather than rapidly, supported by pediatric medicines, orally disintegrating tablets, chewables, syrups, and nutraceuticals. Pricing remains exposed to Chinese manufacturing capacity, vanillin and guaiacol economics, energy costs, regulatory qualification, and substitution by vanillin or other flavor systems.

No major pharmaceutical company publicly reports ethyl vanillin revenue as a standalone product line. Financial analysis therefore depends on market estimates, supplier disclosures, trade data, and end-use assumptions rather than audited segment reporting.

What is ethyl vanillin and how is it used in pharmaceuticals?

Ethyl vanillin is 3-ethoxy-4-hydroxybenzaldehyde, with CAS Registry Number 121-32-4 and molecular formula C9H10O3. It has a stronger vanilla odor and flavor than vanillin and is used at relatively low concentrations.

In pharmaceutical formulations, ethyl vanillin is generally used for:

• Taste masking in pediatric oral medicines
• Flavoring of syrups, suspensions, powders, and chewable tablets
• Improving palatability in orally disintegrating tablets
• Masking bitter or metallic notes from active pharmaceutical ingredients
• Flavor enhancement in nutritional and dietary products
• Flavor systems for oral films, lozenges, and medicated confectionery

Ethyl vanillin does not normally provide the structural or processing functions associated with major excipient classes such as binders, disintegrants, lubricants, fillers, or controlled-release polymers. Its commercial role is closer to a flavoring excipient or organoleptic excipient.

The pharmaceutical value proposition is formulation performance. A small quantity can improve patient acceptability, particularly in pediatric, geriatric, and dysphagia-focused dosage forms.

What is the pharmaceutical regulatory status of ethyl vanillin?

Ethyl vanillin is regulated primarily as a flavoring substance rather than as an active pharmaceutical ingredient.

Regulatory issue	Position
United States food use	Synthetic flavoring substances are regulated under 21 C.F.R. § 172.515
International food evaluation	Ethyl vanillin has been evaluated within the JECFA flavoring-substance framework
European Union	Use is governed by the Union list for flavoring substances under Regulation (EC) No. 1334/2008
Pharmaceutical use	Qualification depends on route, dosage form, concentration, impurity profile, and supplier documentation
Pharmacopeial status	Buyers should confirm the current USP-NF, Ph. Eur., or other applicable monograph and grade requirements
FDA excipient status	Presence in an FDA database or prior use does not automatically establish approval for every route or formulation

The key regulatory distinction is between food-grade flavoring material and pharmaceutical-grade excipient material. Pharmaceutical customers generally require a controlled specification, batch traceability, residual-solvent controls, elemental-impurity data, microbiological limits, allergen statements, and change-control commitments.

FDA’s Inactive Ingredient Database can support a formulation precedent, but it does not replace product-specific regulatory review. Sponsors must establish that the proposed concentration and route are acceptable for the finished dosage form.[1]

How large is the ethyl vanillin pharmaceutical market?

The pharmaceutical segment is difficult to isolate because most commercial market reports combine ethyl vanillin with vanillin, flavoring agents, aroma chemicals, or broader pharmaceutical excipients.

A practical market structure is:

End-use segment	Relative importance for ethyl vanillin	Demand characteristics
Food and beverages	Very high	High volume, price sensitive, broad geographic demand
Confectionery	High	Strong flavor performance but substitution risk
Fragrance and personal care	Moderate	Higher emphasis on sensory profile and sustainability
Pharmaceuticals	Low to moderate	Lower volume, higher qualification and documentation requirements
Nutraceuticals	Moderate	Growth linked to gummies, powders, and oral supplements
Industrial and other uses	Low	Project-specific demand

Pharmaceutical demand is economically attractive because the price per kilogram can exceed commodity food-grade pricing. The segment is still volume-limited. A single pharmaceutical formulation may use only a small quantity of ethyl vanillin, and product demand is tied to marketed dosage units rather than the full active-ingredient market.

The strongest pharmaceutical applications are products in which taste directly affects adherence. These include pediatric antibiotics, antipyretics, cough and cold products, oral nutritional products, and orally disintegrating formulations.

What is driving ethyl vanillin demand in pharmaceuticals?

Pediatric and geriatric dosage forms

Pediatric medicines often require flavor systems because many active ingredients are intensely bitter. Ethyl vanillin can be incorporated into syrups, suspensions, granules, powders, and chewable dosage forms.

The commercial opportunity is strongest where the flavor system improves adherence without requiring a major change to the formulation process.

Orally disintegrating tablets and oral films

Orally disintegrating products release flavor rapidly in the mouth. Ethyl vanillin can provide a recognizable sensory profile, although its use must be balanced against volatility, interaction with excipients, and potential effects on tablet compression or film uniformity.

Taste-masking technologies

Ethyl vanillin is often one component of a broader taste-masking platform. It may be combined with sweeteners, acidulants, bitter blockers, polymer coatings, ion-exchange resins, lipid matrices, or cyclodextrins.

The flavor alone does not eliminate bitterness from a highly potent active ingredient. Formulators may therefore substitute or combine it with encapsulation and coating technologies.

Nutraceutical growth

Gummies, oral powders, effervescent products, and flavored supplements expand the addressable market. Nutraceutical manufacturers can have shorter development cycles than prescription-drug companies, but they are usually more price sensitive and less likely to generate long-term supplier exclusivity.

How does ethyl vanillin compare with vanillin?

Vanillin is the principal substitute and benchmark material. Ethyl vanillin generally has a stronger flavor impact, while vanillin has broader use, larger production volumes, and more established supply chains.

Factor	Ethyl vanillin	Vanillin
Flavor intensity	Higher	Lower
Typical use level	Often lower	Often higher
Cost position	Usually premium	Usually lower
Pharmaceutical role	Taste masking and flavor enhancement	Taste masking and flavor enhancement
Supply base	Narrower	Broader
Substitution risk	Moderate to high	Lower because it is the benchmark
Sensory profile	Strong, sweet, vanilla-like	Familiar vanilla profile
Formulation economics	Attractive when low dosage offsets price	Attractive for cost-sensitive products

Ethyl vanillin can win when lower use levels, stronger masking, or a more pronounced flavor profile justify the higher unit cost. Vanillin remains favored where the formulation has a large batch size, a tight cost target, or an established flavor specification.

Other substitutes include artificial flavor blends, natural vanilla extracts, maltol, ethyl maltol, fruit flavors, sweetener systems, and proprietary taste-masking technologies.

What are the main manufacturing and supply-chain barriers?

Ethyl vanillin is a mature synthetic chemical. The principal barriers are not usually basic chemical know-how or composition-of-matter patents. They are manufacturing consistency, regulatory documentation, process economics, impurity control, and customer qualification.

Key supply-chain variables include:

• Availability and pricing of aromatic feedstocks
• Energy and utility costs
• Chinese production capacity and export logistics
• Waste-treatment and environmental-compliance costs
• Product color and odor consistency
• Residual solvents and trace impurity profiles
• Batch-to-batch sensory variation
• Pharmaceutical change-control requirements
• Dual sourcing and business-continuity expectations

Pharmaceutical customers often qualify a supplier over multiple development and commercial batches. Once a source is approved, switching suppliers can require comparability work, stability assessment, regulatory notification, or a variation filing. This creates practical customer retention even when the underlying compound is not strongly protected by patents.

Supplier qualification is more demanding than ordinary food-grade purchasing. A manufacturer with pharmaceutical documentation can command a premium over a technically equivalent but poorly documented product.

Is ethyl vanillin protected by patents?

The core ethyl vanillin molecule is an old, well-known compound. Broad composition-of-matter patent protection is not a credible commercial barrier for the molecule itself.

Potentially relevant intellectual-property categories include:

1. Manufacturing processes and catalyst systems
2. Purification methods
3. Low-impurity or color-controlled grades
4. Encapsulation and controlled-release flavor systems
5. Taste-masking formulations containing ethyl vanillin
6. Pharmaceutical dosage forms using specified flavor combinations
7. Supplier-specific specifications, trademarks, and trade secrets

A pharmaceutical company may hold patents on a finished dosage form that includes ethyl vanillin, but that does not generally prevent another manufacturer from producing the chemical or using it in an unrelated formulation.

The practical IP position is therefore weak at the molecule level and stronger at the application and process levels. Trade secrets, manufacturing yield, impurity management, and customer qualification are more important than patent exclusivity.

What is the geographic coverage of the ethyl vanillin market?

China is central to global synthetic flavor-chemical supply. Chinese manufacturers benefit from established aromatic-chemical infrastructure, domestic demand, and export capacity. India is relevant as both a pharmaceutical manufacturing base and a potential source of specialty-chemical production.

North America and Europe remain important demand markets because of their pharmaceutical, nutraceutical, and specialty-food industries. These markets place greater weight on documentation, traceability, quality systems, and regulatory compliance.

Region	Market role	Commercial characteristics
China	Major manufacturing and export base	Cost competitive; supply concentration and environmental controls matter
India	Pharmaceutical manufacturing and growing chemical supply	Strong formulation demand; quality qualification is important
Europe	High-value end market	Strict documentation and flavoring compliance requirements
United States	High-value pharmaceutical and nutraceutical market	FDA compliance, supplier qualification, and customer audits
Japan and South Korea	Specialty pharmaceutical and food markets	High quality expectations and established supplier relationships
Latin America	Import-dependent demand	Growth tied to generic medicines and consumer health
Middle East and Africa	Smaller but growing demand	Import logistics and distributor access are central

What is the financial trajectory for ethyl vanillin?

Ethyl vanillin is likely to follow a moderate-growth, margin-differentiated trajectory rather than a high-growth pharmaceutical trajectory.

Period	Expected market condition	Financial implication
Near term	Stable pharmaceutical demand with pricing pressure	Revenue growth depends mainly on volume and customer retention
Medium term	Expansion in pediatric medicines, oral films, supplements, and gummies	Better growth for pharmaceutical-grade and documented suppliers
Longer term	Continued substitution pressure and supplier consolidation	Premiums shift toward quality, traceability, and formulation support

Revenue growth should come from three sources:

• Higher use in oral dosage forms
• Conversion from food-grade to pharmaceutical-grade supply
• Increased demand for documented, dual-sourced, and regionally secure materials

Margin expansion is less certain. Commodity production can experience rapid price erosion when capacity rises. Suppliers with pharmaceutical-grade systems may maintain better margins because customers face switching costs and regulatory burdens.

A useful financial model separates the market into three price tiers:

Tier	Product type	Margin outlook
Commodity	Food-grade bulk ethyl vanillin	Low to moderate
Specialty	High-purity or sensory-controlled material	Moderate
Pharmaceutical	Documented, qualified, change-controlled grade	Highest potential margin

Pharmaceutical customers generally purchase smaller volumes than food manufacturers but can generate better gross profit per kilogram. The most attractive suppliers will combine scale production with pharmaceutical quality systems rather than rely exclusively on pharmaceutical volume.

Which companies and competitors shape the market?

The market is fragmented across chemical producers, flavor houses, distributors, and excipient specialists. Large flavor companies such as Givaudan, IFF, Symrise, and Firmenich-linked operations influence formulation demand and distribution, but they do not necessarily report ethyl vanillin as a separately disclosed product.

Specialty chemical companies and regional Chinese producers often compete on manufacturing cost. Pharmaceutical excipient distributors compete on documentation, inventory availability, technical support, and regional service.

Competitive differentiation generally depends on:

• Reliable capacity
• Consistent odor and assay
• Pharmaceutical documentation
• Global distribution
• Regulatory support
• Low minimum order quantities
• Technical assistance for taste masking
• Dual-source capability
• Stable pricing contracts

Public-company revenue exposure is difficult to quantify because ethyl vanillin is usually embedded in broader flavor, fragrance, food-ingredient, or specialty-chemical segments. Investors should avoid attributing a company’s total flavoring revenue to this compound.

What generic-entry and pharmaceutical product risks exist?

Ethyl vanillin itself does not create a meaningful generic-entry barrier because it is not the protected active ingredient in the relevant pharmaceutical products. The commercial risks arise at the finished-product level.

A generic manufacturer may replace ethyl vanillin with:

• Vanillin
• A proprietary fruit or cream flavor
• A different sweetener system
• A taste-masking coating
• A microencapsulated flavor
• A combination of flavors and bitter blockers

The main risks to ethyl vanillin suppliers are formulation redesign, cost reduction, supplier consolidation, and removal of flavor from products intended for adult patients.

The main demand-supporting factor is regulatory and development friction. Once a pharmaceutical formulation is approved and commercialized, changing a flavor can require stability, sensory, manufacturing, and regulatory work. That friction can preserve incumbent supplier relationships.

What licensing deals and settlement agreements affect ethyl vanillin?

There is no broadly recognized licensing market for the core ethyl vanillin molecule comparable to patented active pharmaceutical ingredients. The relevant commercial arrangements are usually:

• Supply agreements
• Distributor appointments
• Quality agreements
• Formulation-development contracts
• Private-label manufacturing arrangements
• Long-term procurement contracts
• Technology licenses for encapsulation or taste masking

Patent settlement agreements and Paragraph IV litigation are generally not relevant to ethyl vanillin as a standalone excipient. They may become relevant only if ethyl vanillin is included in a patented finished dosage form or a patented delivery system.

How strong is the ethyl vanillin commercial position?

The commercial position is moderate.

Strengths include:

• Strong sensory performance
• Broad compatibility with oral products
• Established synthetic production
• Low use levels
• Relevance to pediatric and patient-centric formulations
• Potential pharmaceutical-grade price premium

Weaknesses include:

• Mature chemistry
• Limited molecule-level IP protection
• Strong substitution by vanillin and flavor blends
• Small pharmaceutical volume
• Exposure to Asian supply concentration
• Limited public revenue transparency
• Dependence on finished-product formulation trends

The compound is best viewed as a specialized, defensible ingredient within qualified pharmaceutical supply chains, not as a high-growth pharmaceutical platform.

Key Takeaways

• Ethyl vanillin is primarily a flavoring and taste-masking excipient, not a structural excipient.
• Pharmaceutical demand is smaller than food, beverage, confectionery, and fragrance demand.
• Pediatric medicines, orally disintegrating tablets, oral films, syrups, and nutraceuticals are the strongest growth applications.
• Vanillin is the principal substitute and sets the cost benchmark.
• The molecule is mature and has limited meaningful composition-of-matter patent protection.
• Manufacturing consistency, documentation, supplier qualification, and regulatory support create the main commercial barriers.
• Pharmaceutical-grade material can earn higher margins than commodity food-grade material.
• Public companies generally do not disclose ethyl vanillin revenue separately.
• Generic-entry litigation, Paragraph IV challenges, and Orange Book listings are generally not relevant to the ingredient itself.
• Financial performance should be modeled through volume growth, price tier, pharmaceutical qualification, regional supply concentration, and substitution risk.

FAQs

Is ethyl vanillin safe as a pharmaceutical excipient?

Safety depends on route, dose, concentration, impurity profile, and the finished product. Its use must be supported by applicable regulatory and formulation data rather than by food-use status alone.

Is ethyl vanillin listed in the FDA Inactive Ingredient Database?

The FDA Inactive Ingredient Database should be checked for the specific route and dosage form. A listing does not establish universal acceptance for all pharmaceutical applications.

Can ethyl vanillin be used in pediatric medicines?

Yes. Its strongest pharmaceutical use case is flavoring and taste masking in pediatric oral formulations, subject to concentration, excipient compatibility, and regulatory review.

Is ethyl vanillin more expensive than vanillin?

Usually. Ethyl vanillin generally commands a premium because of its stronger flavor intensity and lower potential use level, although market prices vary by grade, origin, volume, and contract terms.

Does ethyl vanillin have pharmaceutical patent protection?

The core molecule is mature and is unlikely to have enforceable broad composition-of-matter protection. Patents may still cover manufacturing processes, encapsulation systems, or finished pharmaceutical formulations containing it.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (2024). 21 C.F.R. § 172.515: Synthetic flavoring substances and adjuvants. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/section-172.515

3. European Parliament and Council of the European Union. (2008). Regulation (EC) No 1334/2008 on flavourings and certain food ingredients with flavouring properties for use in and on foods. Official Journal of the European Union.

4. Joint FAO/WHO Expert Committee on Food Additives. (2002). Compendium of food additive specifications: Addendum 10. Food and Agriculture Organization of the United Nations and World Health Organization.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

6. International Council for Harmonisation. (2022). ICH Q3C(R8): Impurities: Guideline for residual solvents. ICH.

7. U.S. Food and Drug Administration. (2016). The FDA’s process for reviewing and evaluating flavoring substances. FDA.